Drugs / Monalizumab
Monalizumab
also known as
IPH2201 · IPH-2201 (ANTI-NKG2A) · Monalizumab (IPH2201) · NN-8765 · NN8765-3658 · NNC 0141-0000-0100
Monoclonal antibody targets KLRC1
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03801902 | Oct 2019 → Oct 2021 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02921685 | Nov 2016 → May 2019 | hematopoietic and lymphoid system neoplasm | Institut Paoli-Calmettes | Unknown | No outcome recorded |
| Phase 1 | NCT02459301 | Sep 2015 → Nov 2017 | female reproductive organ cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT01370902 | May 2011 → Mar 2014 | rheumatoid arthritis | Innate Pharma | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03307941 | Jul → Dec 2017 | esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma | Jules Bordet Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02671435 | Feb 2016 → Oct 2021 overdue | cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02643550 | Dec 2015 → Mar 2023 | head and neck neoplasm | Innate Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT02557516 | Nov 2015 → Oct 2018 | B-cell chronic lymphocytic leukemia | Innate Pharma | Terminated | No outcome recorded |
| Phase 1/2 | NCT02331875 | Dec 2014 → Dec 2016 | oral cavity squamous cell carcinoma | Innate Pharma | Terminated | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07146230 | Sep 2026 → Apr 2028 expected | non-small cell lung carcinoma | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06769126 | Nov 2025 → Dec 2028 expected | small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2 | NCT06503614 | Feb 2025 → Dec 2027 expected | non-invasive bladder urothelial carcinoma | John Sfakianos | Recruiting | No outcome recorded |
| Phase 2 | NCT06152523 | Dec 2023 → Dec 2028 | colorectal cancer | Assistance Publique - Hôpitaux de Paris | Withdrawn | No outcome recorded |
| Phase 2 | NCT05903092 | Sep 2023 → Oct 2029 expected | small cell lung carcinoma | Hirva Mamdani | Recruiting | No outcome recorded |
| Phase 2 | NCT05061550 | Apr 2022 → May 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06892223 | Dec 2021 → Mar 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Istituto Clinico Humanitas | Recruiting | No outcome recorded |
| Phase 2 | NCT04307329 | Mar 2021 → Jan 2023 | breast cancer | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT04145193 | Oct 2020 → Mar 2024 | colorectal cancer | MedImmune LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04333914 | Apr 2020 → Jul 2021 | COVID-19 | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT03833440 | Oct 2019 → Oct 2024 | non-small cell lung carcinoma | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 2 | NCT03794544 | Mar 2019 → Jan 2021 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03822351 | Dec 2018 → Jul 2023 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03088059 | Nov 2017 → Jun 2025 | head and neck squamous cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05221840 | Feb 2022 → Sep 2026 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04590963 | Oct 2020 → May 2022 overdue | head and neck squamous cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monalizumab | “Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.” PMID 31308062 ↗ Jul 2019 |
| Known as | IPH-2201 (ANTI-NKG2A) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297787 ↗ |
| Known as | IPH2201 | “This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK),...” NCT02671435 ↗5“Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.” PMID 31308062 ↗ Jul 2019 “durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201)” NCT05221840 ↗ “Monalizumab (IPH2201)” NCT03833440 ↗ |
| Known as | Monalizumab (IPH2201) | “Monalizumab (IPH2201)” NCT03822351 ↗ |
| Known as | NN-8765 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297787 ↗ |
| Known as | NN8765-3658 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297787 ↗ |
| Known as | NNC 0141-0000-0100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01370902 ↗ |
| Action | Inhibit | “PURPOSE: Monalizumab binds CD94/NKG2A, preventing HLA-E inhibition of tumor lymphocytes.” PMID 31308062 ↗ Jul 2019 |
| Modality | Monoclonal antibody | “Monalizumab is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor” PMID 36852723 ↗ Apr 2023 |
| Route | Subcutaneous | “Single dose administered subcutaneously (under the skin)” NCT01370902 ↗ |
| Target | KLRC1 | “durvalumab plus monalizumab (anti-NKG2A)” PMID 37707791 ↗ Nov 2023 |